Insider transactions

Stephen C Farrell

CIK 1188757 · President & CEO · last filed 2025-03-06

Stephen C Farrell is a President & CEO who has filed 60 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing shows the insider exercised options covering $138.9K of STAA on Mar 6, 2025. Across all open-market trades the lifetime net is −$4.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $776.9K across reported positions. 13 SEC filings were submitted jointly with Lineage Cell Therapeutics, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$776.9K
Companies
8
Total Filings
60
Lifetime Open-Market Net
-$4.77M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
701 EDGEWATER DRIVE
SUITE 360
WAKEFIELD, MA 01880
Related Filers
Lineage Cell Therapeutics, Inc. — 13 joint filings, latest 2020-07-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
STAA President & CEO 35,156 $22.10 $776.9K $0 20 2025-03-06
Convey Health Solutions Holdings, Inc. (CNVY) Delisted CHIEF EXECUTIVE OFFICER 636,862 $10.51 $6.69M $585.0K 2 2022-03-30
LCTX Director — $0.92 — $0 1 2020-07-02
Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Director 97,450 — — $350.4K 10 2018-07-03
QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted Director 15,433 — — -$2.57M 11 2014-03-11
Stream Global Services, Inc. (OOO.WS) Delisted Executive Vice President & CFO 3,640 — — $9.1K 4 2008-12-18
QUESTCOR PHARMACEUTICALS INC (QSC) Delisted Director — — — $0 3 2008-01-03
POLYMEDICA CORP (PSTA) Delisted President 0 — — -$3.14M 6 2007-11-13

Recent Filings

60 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-03-06 STAA Exer (M) +20,000 $138.9K EDGAR
2025-02-28 STAA Grant (A) — $0 EDGAR
2024-06-24 STAA Grant (A) +2,244 $0 EDGAR
2024-01-02 STAA Grant (A) +921 $28.7K EDGAR
2023-11-06 STAA Grant (A) +3,000 $105.5K EDGAR
2023-10-03 STAA Grant (A) +715 $28.7K EDGAR
2023-06-16 STAA Exer (M) +1,709 $0 EDGAR
2022-10-12 — Disp (D) −163,373 -$1.72M
2022-06-17 STAA Exer (M) +355 $0 EDGAR
2022-03-30 Convey Health Solutions Holdings, Inc. (CNVY) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 60
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.